While therapeutic modulation of hypoxia and oxidative stress cannot be excluded on the basis of our results as viable therapeutic strategies in cancer [11,12,20], our results do contradict a growing body of experimental reports of catalase administration effects [[2], [3], [4], [5], [6], [7], [8], [9], [10]]. The gene discussed is CAT; the disease is cancer.